症状性多发性骨髓瘤中急性肾损伤的管理
症状性多发性骨髓瘤常因单克隆游离轻链在远端小管与尿调节素沉淀而并发急性肾损伤,即轻链管型肾病。早期诊断和明确AKI病因对优化管理、避免慢性肾损伤至关重要。轻链管型肾病的肾脏恢复需紧急积极补液、纠正诱因及高效抗浆细胞化疗;硼替佐米联合大剂量地塞米松是初诊标准方案,高截留量血液透析联合化疗可能提高肾脏反应恢复率。
要点
- 轻链管型肾病需紧急积极补液、纠正诱因及高效抗浆细胞化疗。
- 初诊患者标准方案为硼替佐米联合大剂量地塞米松。
- 需透析的轻链管型肾病患者,化疗联合高截留量血液透析可能提高肾脏恢复率。
核心结论
- 轻链管型肾病导致的急性肾损伤需紧急干预以促进肾脏恢复,避免慢性肾损伤。
- 硼替佐米联合大剂量地塞米松是初诊症状性骨髓瘤患者的标准方案。
- 高截留量血液透析联合化疗可能提高需透析的轻链管型肾病患者的肾脏反应恢复率。
研究设计与样本
- 原文为综述,未报告系统检索范围或样本量。
主要发现
- 轻链管型肾病是最常见的AKI机制,由单克隆游离轻链在远端小管与尿调节素沉淀所致。
- 肾脏预后似乎取决于管型形成范围及间质纤维化/肾小管萎缩程度。
- 随机研究结果有争议,但近期数据提示高截留量血液透析联合化疗可能提高肾脏反应恢复率。
关键数值与推荐
- 初诊患者标准方案:硼替佐米联合大剂量地塞米松。
- 可加用环磷酰胺或免疫调节剂以改善游离轻链反应,但虚弱患者需关注耐受性。
- 抗CD38单克隆抗体的作用尚待进一步研究确认。
临床怎么用
- 早期诊断并明确AKI病因,紧急积极补液、纠正诱因并启动高效抗浆细胞化疗。
- 对需透析的轻链管型肾病患者,可考虑化疗联合高截留量血液透析。
- 肾活检有助于指导管理并评估肾脏预后。
- 因骨髓瘤患者预期寿命改善,选定候选者可考虑肾移植。
局限性
- 抗CD38单克隆抗体的疗效与耐受性仅在无肾功能损害患者中记录,需进一步研究。
- 高截留量血液透析联合化疗的随机研究结果存在争议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Symptomatic multiple myeloma is commonly complicated by acute kidney injury through various mechanisms. The most frequent is the precipitation of monoclonal free light chains with uromodulin in the distal tubules, defining light chain cast nephropathy. Early diagnosis and identification of the cause of acute kidney injury are required for optimizing management and avoiding chronic kidney injury that strongly affects quality of life and patient survival. In light chain cast nephropathy, often manifesting with severe acute kidney injury, renal recovery requires urgent intervention based on vigorous rehydration, correction of precipitating factors, and efficient anti-plasma cell chemotherapy to rapidly reduce the secretion of nephrotoxic free light chains. Currently, the association of the proteasome inhibitor bortezomib with high-dose dexamethasone is the standard regimen in newly diagnosed patients. The addition of another drug such as cyclophosphamide or an immunodulatory agent may improve free light chain response but raises tolerance concerns in frail patients. Further studies are warranted to confirm the role of anti-CD38 monoclonal antibodies, whose efficacy and tolerance have been documented in patients without renal impairment. Despite controversial results from randomized studies, recent data suggest that in patients with light chain cast nephropathy and acute kidney injury requiring dialysis, the combination of chemotherapy with free light chain removal through high-cutoff hemodialysis may increase renal response recovery rates. Kidney biopsy may be helpful in guiding management and assessing renal prognosis that appears to depend on the extent of cast formation and interstitial fibrosis/tubular atrophy. Because of continuous improvement in life expectancy of patients with multiple myeloma, renal transplantation is likely to be increasingly considered in selected candidates.
引用
- Bridoux F, Leung N, Belmouaz M, et al. Management of acute kidney injury in symptomatic multiple myeloma. Kidney Int. 2021. PMID: 33440212. doi:10.1016/j.kint.2020.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。